Marksans Pharma Intrinsic Value
MARKSANS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹190.96 | ₹152.77 - ₹229.15 | +4.8% | EPS: ₹8.68, Sector P/E: 22x |
| Book Value Method | asset | ₹455.48 | ₹409.93 - ₹501.03 | +150.0% | Book Value/Share: ₹553.11, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹364.38 | ₹327.94 - ₹400.82 | +100.0% | Revenue/Share: ₹659.56, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹364.38 | ₹327.94 - ₹400.82 | +100.0% | EBITDA: ₹664.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹405.86 | ₹324.69 - ₹487.03 | +122.8% | CF Growth: 3.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹55.55 | ₹49.99 - ₹61.11 | -69.5% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹134.11 | ₹120.70 - ₹147.52 | -26.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹364.38 | ₹327.94 - ₹400.82 | +100.0% | ROE: 15.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹328.67 | ₹295.80 - ₹361.54 | +80.4% | EPS: ₹8.68, BVPS: ₹553.11 |
Want to compare with current market value? Check MARKSANS share price latest .
Valuation Comparison Chart
MARKSANS Intrinsic Value Analysis
What is the intrinsic value of MARKSANS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Marksans Pharma (MARKSANS) is ₹364.38 (median value). With the current market price of ₹182.19, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹55.55 to ₹455.48, indicating ₹55.55 - ₹455.48.
Is MARKSANS undervalued or overvalued?
Based on our multi-method analysis, Marksans Pharma (MARKSANS) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.07 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.30 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 15.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Marksans Pharma
Additional stock information and data for MARKSANS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹207 Cr | ₹183 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹230 Cr | ₹160 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹237 Cr | ₹108 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹99 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹179 Cr | ₹157 Cr | Positive Free Cash Flow | 8/10 |